Form 4: Nautilus Biotechnology Executive Granted Stock Options

Kentaro Suzuki, Chief Marketing Officer of Nautilus Biotechnology, receives stock options for 375,000 shares.

Summary

• Kentaro Suzuki, the Chief Marketing Officer of Nautilus Biotechnology, Inc., was granted stock options on September 16, 2024.
• The options grant covers 375,000 shares of Nautilus Biotechnology's common stock.
• The exercise price for the options is $2.96 per share.
• The options vest over a four-year period, with 25% vesting on the first anniversary of the Vesting Commencement Date (September 16, 2024), and the remainder vesting monthly over the following 36 months, contingent upon continued service.
• The options expire on September 16, 2034.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to executive compensation. It's generally neutral, but the granting of stock options can be seen as a positive sign of confidence in the company's future.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Nautilus Biotechnology.
• Comparable companies such as Pacific Biosciences, Twist Bioscience, and Quantum-Si also utilize stock options as part of their executive compensation plans.
• The vesting schedule of 25% after one year and the remainder monthly over the next 36 months is a typical vesting structure.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company growth.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates